Haeri Roh

427 total citations
11 papers, 370 citations indexed

About

Haeri Roh is a scholar working on Radiology, Nuclear Medicine and Imaging, Molecular Biology and Oncology. According to data from OpenAlex, Haeri Roh has authored 11 papers receiving a total of 370 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Radiology, Nuclear Medicine and Imaging, 6 papers in Molecular Biology and 6 papers in Oncology. Recurrent topics in Haeri Roh's work include Monoclonal and Polyclonal Antibodies Research (6 papers), HER2/EGFR in Cancer Research (5 papers) and Cytokine Signaling Pathways and Interactions (3 papers). Haeri Roh is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (6 papers), HER2/EGFR in Cancer Research (5 papers) and Cytokine Signaling Pathways and Interactions (3 papers). Haeri Roh collaborates with scholars based in United States and South Korea. Haeri Roh's co-authors include Jeffrey A. Drebin, James A. Pippin, Douglas W. Green, Elizabeth J. Keath, Fatima Abidi, Christopher B. Hirose, Nahush A. Mokadam, John Sarantopoulos, Duyoung Min and Jiyeon Yoon and has published in prestigious journals such as Oncogene, Infection and Immunity and Journal of the American College of Surgeons.

In The Last Decade

Haeri Roh

9 papers receiving 359 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Haeri Roh United States 8 274 136 83 36 27 11 370
T.C. Willcocks United Kingdom 10 212 0.8× 105 0.8× 55 0.7× 55 1.5× 47 1.7× 13 406
Pegah Johansson Sweden 12 213 0.8× 118 0.9× 21 0.3× 35 1.0× 54 2.0× 26 342
Shigeyuki Iijima Japan 7 189 0.7× 158 1.2× 114 1.4× 28 0.8× 11 0.4× 9 376
Naomi Ohbayashi Japan 10 206 0.8× 91 0.7× 13 0.2× 36 1.0× 48 1.8× 13 345
Joseph Colofiore United States 13 198 0.7× 152 1.1× 14 0.2× 26 0.7× 29 1.1× 24 329
Ruea-Yea Huang United States 10 224 0.8× 185 1.4× 25 0.3× 11 0.3× 48 1.8× 11 375
H. W. von Heyden Germany 10 162 0.6× 63 0.5× 26 0.3× 27 0.8× 17 0.6× 33 293
Anna Ju South Korea 9 183 0.7× 64 0.5× 78 0.9× 10 0.3× 28 1.0× 14 323
E Turpin France 10 197 0.7× 144 1.1× 39 0.5× 13 0.4× 94 3.5× 20 353
Donald P. Evenson United States 5 232 0.8× 84 0.6× 28 0.3× 9 0.3× 33 1.2× 9 385

Countries citing papers authored by Haeri Roh

Since Specialization
Citations

This map shows the geographic impact of Haeri Roh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haeri Roh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haeri Roh more than expected).

Fields of papers citing papers by Haeri Roh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haeri Roh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haeri Roh. The network helps show where Haeri Roh may publish in the future.

Co-authorship network of co-authors of Haeri Roh

This figure shows the co-authorship network connecting the top 25 collaborators of Haeri Roh. A scholar is included among the top collaborators of Haeri Roh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haeri Roh. Haeri Roh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
2.
Kim, Dong‐Wan, Se‐Hoon Lee, Jae‐Lyun Lee, et al.. (2024). 698 A phase I, open-label, multinational, multicenter, dose escalation and expansion study of BH3120 (4–1BB x PD-L1 BsAb) in patients with advanced or metastatic solid tumors. Regular and Young Investigator Award Abstracts. A800–A800.
3.
Green, Douglas W., Haeri Roh, James A. Pippin, & Jeffrey A. Drebin. (2001). β-Catenin Antisense Treatment Decreases β-Catenin Expression and Tumor Growth Rate in Colon Carcinoma Xenografts. Journal of Surgical Research. 101(1). 16–20. 59 indexed citations
4.
Roh, Haeri, et al.. (2001). Suppression of beta-catenin inhibits the neoplastic growth of APC-mutant colon cancer cells.. PubMed. 61(17). 6563–8. 87 indexed citations
5.
Roh, Haeri, James A. Pippin, & Jeffrey A. Drebin. (2000). Down-regulation of HER2/neu expression induces apoptosis in human cancer cells that overexpress HER2/neu.. PubMed. 60(3). 560–5. 96 indexed citations
6.
Green, Douglas W., Haeri Roh, James A. Pippin, & Jeffrey A. Drebin. (2000). Antisense oligonucleotides: an evolving technology for the modulation of gene expression in human disease1. Journal of the American College of Surgeons. 191(1). 93–105. 28 indexed citations
7.
Roh, Haeri, et al.. (2000). HER2/neu antisense targeting of human breast carcinoma. Oncogene. 19(53). 6138–6143. 31 indexed citations
8.
Roh, Haeri, et al.. (1999). Synergistic antitumor effects of HER2/neu antisense oligodeoxynucleotides and conventional chemotherapeutic agents. Surgery. 126(2). 413–421. 21 indexed citations
9.
Roh, Haeri, et al.. (1999). Synergistic antitumor effects of HER2/neu antisense oligodeoxynucleotides and conventional chemotherapeutic agents. Surgery. 126(2). 413–421. 3 indexed citations
10.
Roh, Haeri, et al.. (1998). Antisense Oligonucleotides Specific for the HER2/neu Oncogene Inhibit the Growth of Human Breast Carcinoma Cells That Overexpress HER2/neu. Journal of Surgical Research. 77(1). 85–90. 26 indexed citations
11.
Abidi, Fatima, Haeri Roh, & Elizabeth J. Keath. (1998). Identification and Characterization of a Phase-Specific, Nuclear DNA Binding Protein from the Dimorphic Pathogenic Fungus Histoplasma capsulatum. Infection and Immunity. 66(8). 3867–3873. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by T.C. Willcocks Breakdown of academic impact, for papers by Pegah Johansson Breakdown of academic impact, for papers by Shigeyuki Iijima Breakdown of academic impact, for papers by Naomi Ohbayashi Breakdown of academic impact, for papers by Joseph Colofiore Breakdown of academic impact, for papers by Ruea-Yea Huang Breakdown of academic impact, for papers by H. W. von Heyden Breakdown of academic impact, for papers by Anna Ju Breakdown of academic impact, for papers by E Turpin Breakdown of academic impact, for papers by Donald P. Evenson
Rankless by CCL
2026